PPARG and breast carcinoma: For example, the PPAR-γ agonist troglitazone increased cellproliferation of breast cancer cells in low concentrations (<5 μM), whilehigher concentrations of troglitazone (100 μM) inhibited cell growth [38].These investigations corroborate our published data in melanoma cells.